ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]

read more

Bevacizumab plus erlotinib combination for advanced HLRCC

A recent study, published in Cancer Research and Treatment in March 2019, provides the first real-world evidence of the promising treatment of advanced hereditary leiomyomatosis and renal cell carcinoma (HLRCC), a rare genetic syndrome resulting from mutations in the gene that makes an enzyme called fumarate hydratase. Ten patients with advanced HLRCC-associated renal cell carcinoma […]

read more

Treatment for hereditary leiomyomatosis renal cell carcinoma (HLRCC): a rare and aggressive form of kidney cancer

In this video, Dr W. Marston Linehan, chief of the Urologic Oncology Branch of the National Cancer Institute in America, discusses the treatment of hereditary leiomyomatosis and renal cell carcinoma (HLRCC). HLRCC is very rare inherited condition, in which patients are at risk of developing┬ánon-cancerous (benign) tumours in the muscle under the skin (cutaneous leiomyomas), […]

read more
Showing all 3 results